Clinical Trial Detail

NCT ID NCT02292550
Title Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Ceritinib + Ribociclib

Age Groups: adult

Additional content available in CKB BOOST